[{"id":"ea505106-f0f3-438c-81cb-5a4b65a69585","acronym":"","url":"https://clinicaltrials.gov/study/NCT02452554","created_at":"2021-01-18T11:45:46.897Z","updated_at":"2024-07-02T16:36:18.487Z","phase":"Phase 2","brief_title":"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma","source_id_and_acronym":"NCT02452554","lead_sponsor":"Children's Oncology Group","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/12/2015","start_date":" 10/12/2015","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-01-13"},{"id":"792a891b-6076-4a79-9e41-755c5c16dc11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02420873","created_at":"2021-01-18T11:34:35.992Z","updated_at":"2024-07-02T16:37:07.404Z","phase":"Phase 2","brief_title":"An Open-label Phase II Study of Lorvotuzumab Mertansine","source_id_and_acronym":"NCT02420873","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["FLT3 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/12/2015","start_date":" 05/12/2015","primary_txt":" Primary completion: 06/06/2017","primary_completion_date":" 06/06/2017","study_txt":" Completion: 06/06/2017","study_completion_date":" 06/06/2017","last_update_posted":"2018-08-28"}]